YI
Roles
Therapeutic Areas
MediciNova Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MN-166 (ibudilast) | Progressive Multiple Sclerosis | Phase 3 |
| MN-221 | Acute Exacerbations of Asthma | Phase 3 |
| MN-001 | Liver Fibrosis (NASH) | Phase 2 |
| MN-029 | Oncology (unspecified) | Not Disclosed |
| MN-305 | Not specified | Not Disclosed |
| MN-246 | Not specified | Not Disclosed |
| Portfolio Candidate | Solid Tumor Cancers | Preclinical/Clinical |
Leadership Team at MediciNova
KM
Kazuko Matsuda
Chief Medical Officer
DH
David H. Crean
Chief Business Officer
JJ
Jason J. Kruger
Chief Financial Officer
HN
Hideki Nagao
Member of the Board of Directors
KM
Kazuko Matsuda
Member of the Board of Directors
CB
Carolyn Beaver
Member of the Board of Directors